Canadian drugmaker raised prices for NHS by more than 5,500%

A Canadian drugmaker has been accused of abusing its dominant position by raising the price of an essential drug more than 5,500 per cent for the National Health Service Concordia Healthcare forced the NHS and UK taxpayers “to pay over the odds for imp